BACKGROUND: We conducted a phase I study to determine the maximum tolerated dose of @entity1205 in combination with @entity136 for @entity1 with refractory solid @entity5 . METHODS: From January 1998 to November 1999, we treated 28 @entity1 on a phase I protocol with @entity136 given at a constant dose of 800 mg/m2 i.v. over 30 minutes on days 1, 8, and 15. @entity1205 was administered by a phase I schedule over 1 hour on day 1 of a 28-day cycle with a starting dose of 50 mg/m2 and increased by increments of 10 mg/m2 based on dose-limiting @entity137 (DLT) that occurred in the first cycle. RESULTS: @entity1398 and @entity882 were the dose-limiting @entity137 . The maximum tolerated dose was 60 mg/m2. The most significant nonhematologic @entity137 included @entity1295 , @entity390 , @entity391 , @entity33 , and @entity56 reactions. There was one partial response at 15 months in a @entity1 with @entity356 and six @entity1 with stable disease for 4.0 to 15.0 months. CONCLUSIONS: The maximum tolerated dose of @entity1205 with @entity136 is 60 mg/m2. A Phase II study in selected primary sites is planned.

A phase I study of XXXX and @entity1205 for advanced stage solid @entity5 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel', 'Docetaxel'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['Neutropenia'] @entity56 :: ('MESH:D004342', 'Disease') :: ['hypersensitivity'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer']
@entity136 :: (MESH:C056507,Chemical) :: ['gemcitabine']
